Bristol Myers Squibb completes acquisition of Karuna Therapeutics, Inc. to strengthen its neuroscience portfolio
Mar 18, 2024•over 1 year ago
Acquiring Company
Bristol Myers Squibb
Acquired Company
Karuna Therapeutics
Description
Bristol Myers Squibb has successfully completed the acquisition of Karuna Therapeutics, Inc. This acquisition adds KarXT, an antipsychotic with a novel mechanism of action, and Karuna’s early-stage and pre-clinical pipeline to Bristol Myers Squibb’s portfolio, reinforcing its commitment to strengthening its growth profile in the latter half of the decade and beyond.
M&A Insights
Based on deal dataIntegration timeline
70% of M&A integrations take 12-24 months to complete
Tech stack consolidation
83% of merged companies consolidate technology vendors within first year
Post-acquisition investment
Companies increase IT spending by 23% on average after acquisitions
Success factor
M&A deals with strong technology integration plans are 2.5x more likely to succeed